In Vitro Recapitulating of TP53 Mutagenesis in Hepatocellular Carcinoma Associated With Dietary Aflatoxin B1 Exposure

Gastroenterology

Volumn 137, Issue 3, 2009, Pages

  Besaratinia, Ahmad ^a   Kim, Sang in ^a   Hainaut, Pierre ^b   Pfeifer, Gerd P ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; IMIDAZOLE; PROTEIN P53;

ANIMAL CELL; ARTICLE; CYTOTOXICITY; DNA ADDUCT; DNA DAMAGE; DNA FOOTPRINTING; DNA SEQUENCE; FIBROBLAST; GENE MUTATION; IN VITRO STUDY; LIVER CELL CARCINOMA; MOUSE; MUTAGENESIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 69249129569     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.06.002     Document Type: Article

References (49)

1. El-Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007) 2557-2576
2. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
3. Bosch F.X., Ribes J., Diaz M., et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (2004) S5-S16
4. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25 (2005) 143-154
5. Yu M.C., and Yuan J.M. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127 (2004) S72-S78
6. Kensler T.W., Qian G.S., Chen J.G., et al. Translational strategies for cancer prevention in liver. Nat Rev Cancer 3 (2003) 321-329
7. Staib F., Hussain S.P., Hofseth L.J., et al. TP53 and liver carcinogenesis. Hum Mutat 21 (2003) 201-216
8. Smela M.E., Currier S.S., Bailey E.A., et al. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis 22 (2001) 535-545
9. Wild C.P., and Turner P.C. The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis 17 (2002) 471-481
10. Petitjean A., Mathe E., Kato S., et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28 (2007) 622-629
11. Hussain S.P., Schwank J., Staib F., et al. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26 (2007) 2166-2176
12. Ueng Y.F., Shimada T., Yamazaki H., et al. Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chem Res Toxicol 8 (1995) 218-225
13. Gallagher E.P., Kunze K.L., Stapleton P.L., et al. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Toxicol Appl Pharmacol 141 (1996) 595-606
14. Mace K., Aguilar F., Wang J.S., et al. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis 18 (1997) 1291-1297
15. Essigmann J.M., Croy R.G., Nadzan A.M., et al. Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro. Proc Natl Acad Sci U S A 74 (1977) 1870-1874
16. Eaton D.L., and Gallagher E.P. Mechanisms of aflatoxin carcinogenesis. Annu Rev Pharmacol Toxicol 34 (1994) 135-172
17. Johnson W.W., and Guengerich F.P. Reaction of aflatoxin B1 exo-8,9-epoxide with DNA: kinetic analysis of covalent binding and DNA-induced hydrolysis. Proc Natl Acad Sci U S A 94 (1997) 6121-6125
18. Guengerich F.P., Johnson W.W., Shimada T., et al. Activation and detoxication of aflatoxin B1. Mutat Res 402 (1998) 121-128
19. Groopman J.D., Croy R.G., and Wogan G.N. In vitro reactions of aflatoxin B1-adducted DNA. Proc Natl Acad Sci U S A 78 (1981) 5445-5449
20. Bailey E.A., Iyer R.S., Stone M.P., et al. Mutational properties of the primary aflatoxin B1-DNA adduct. Proc Natl Acad Sci U S A 93 (1996) 1535-1539
21. Jones W.R., Johnston D.S., and Stone M.P. Site-specific synthesis of aflatoxin B(1) adducts within an oligodeoxyribonucleotide containing the human p53 codon 249 sequence. Chem Res Toxicol 12 (1999) 707-714
22. Smela M.E., Hamm M.L., Henderson P.T., et al. The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc Natl Acad Sci U S A 99 (2002) 6655-6660
23. Jakubczak J.L., Merlino G., French J.E., et al. Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage λ transgene target. Proc Natl Acad Sci U S A 93 (1996) 9073-9078
24. Besaratinia A., and Pfeifer G.P. Investigating human cancer etiology by DNA lesion footprinting and mutagenicity analysis. Carcinogenesis 27 (2006) 1526-1537
25. Lambert I.B., Singer T.M., Boucher S.E., et al. Detailed review of transgenic rodent mutation assays. Mutat Res 590 (2005) 1-280
26. Zhang Y.J., Chen C.J., Lee C.S., et al. Aflatoxin B1-DNA adducts and hepatitis B virus antigens in hepatocellular carcinoma and non-tumorous liver tissue. Carcinogenesis 12 (1991) 2247-2452
27. Boiteux S., and Guillet M. Abasic sites in DNA: repair and biological consequences in Saccharomyces cerevisiae. DNA Repair (Amst) 3 (2004) 1-12
28. Chen H.H., Kontaraki J., Bonifer C., et al. Terminal transferase-dependent PCR (TD-PCR) for in vivo UV photofootprinting of vertebrate cells. Sci STKE 2001 (2001) PL1
29. Denissenko M.F., Cahill J., Koudriakova T.B., et al. Quantitation and mapping of aflatoxin B1-induced DNA damage in genomic DNA using aflatoxin B1-8,9-epoxide and microsomal activation systems. Mutat Res 425 (1999) 205-211
30. Denissenko M.F., Koudriakova T.B., Smith L., et al. The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. Oncogene 17 (1998) 3007-3014
31. Besaratinia A., Synold T.W., Chen H.H., et al. DNA lesions induced by UV A1 and B radiation in human cells: comparative analyses in the overall genome and in the p53 tumor suppressor gene. Proc Natl Acad Sci U S A 102 (2005) 10058-10063
32. Besaratinia A., and Pfeifer G.P. DNA-lesion mapping in mammalian cells. Methods 48 (2009) 35-39
33. Mellon I., Spivak G., and Hanawalt P.C. Selective removal of transcription-blocking DNA damage from the transcribed strand of the mammalian DHFR gene. Cell 51 (1987) 241-249
34. Wogan G.N., Hecht S.S., Felton J.S., et al. Environmental and chemical carcinogenesis. Semin Cancer Biol 14 (2004) 473-486
35. Thilly W.G. Have environmental mutagens caused oncomutations in people?. Nat Genet 34 (2003) 255-259
36. Prieto-Alamo M.J., Jurado J., Abril N., et al. Mutational specificity of aflatoxin B1. Comparison of in vivo host-mediated assay with in vitro S9 metabolic activation. Carcinogenesis 17 (1996) 1997-2002
37. Doi A.M., Patterson P.E., and Gallagher E.P. Variability in aflatoxin B(1)-macromolecular binding and relationship to biotransformation enzyme expression in human prenatal and adult liver. Toxicol Appl Pharmacol 181 (2002) 48-59
38. Obach R.S., and Dobo K.L. Comparison of metabolite profiles generated in Aroclor-induced rat liver and human liver subcellular fractions: considerations for in vitro genotoxicity hazard assessment. Environ Mol Mutagen 49 (2008) 631-641
39. Hertzog P.J., Lindsay Smith J.R., Garner R.C., et al. A high-pressure liquid chromatography study on the removal of DNA-bound aflatoxin B1 in rat liver and in vitro. Carcinogenesis 1 (1980) 787-793
40. Croy R.G., and Wogan G.N. Temporal patterns of covalent DNA adducts in rat liver after single and multiple doses of aflatoxin B1. Cancer Res 41 (1981) 197-203
41. Jones W.R., Johnston D.S., and Stone M.P. Refined structure of the doubly intercalated d(TATAFBGCATA)2 aflatoxin B1 adduct. Chem Res Toxicol 11 (1998) 873-881
42. Giri I., Johnston D.S., and Stone M.P. Mispairing of the 8,9-dihydro-8-(N7-guanyl)-9-hydroxy-aflatoxin B1 adduct with deoxyadenosine results in extrusion of the mismatched dA toward the major groove. Biochemistry 41 (2002) 5462-5472
43. Leadon S.A., Tyrrell R.M., and Cerutti P.A. Excision repair of aflatoxin B1-DNA adducts in human fibroblasts. Cancer Res 41 (1981) 5125-5129
44. Alekseyev Y.O., Hamm M.L., and Essigmann J.M. Aflatoxin B1 formamidopyrimidine adducts are preferentially repaired by the nucleotide excision repair pathway in vivo. Carcinogenesis 25 (2004) 1045-1051
45. Madden C.R., Finegold M.J., and Slagle B.L. Altered DNA mutation spectrum in aflatoxin b1-treated transgenic mice that express the hepatitis B virus x protein. J Virol 76 (2002) 11770-11774
46. Paget V., Sichel F., Garon D., et al. Aflatoxin B1-induced TP53 mutational pattern in normal human cells using the FASAY (functional analysis of separated alleles in yeast). Mutat Res 656 (2008) 55-61
47. You Y.H., and Pfeifer G.P. Similarities in sunlight-induced mutational spectra of CpG-methylated transgenes and the p53 gene in skin cancer point to an important role of 5-methylcytosine residues in solar UV mutagenesis. J Mol Biol 305 (2001) 389-399
48. Aguilar F., Hussain S.P., and Cerutti P. Aflatoxin B1 induces the transversion of G to T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A 90 (1993) 8586-8590
49. Maxam A.M., and Gilbert W. A new method for sequencing DNA. Proc Natl Acad Sci U S A 74 (1977) 560-564